Breast invasive carcinoma with a choriocarcinomatous pattern

Joanna B. Wysocka, Joanna Lompart, A. Pietruszka, Mirosława Puskullouglu, A. Grela-Wojewoda
{"title":"Breast invasive carcinoma with a choriocarcinomatous pattern","authors":"Joanna B. Wysocka, Joanna Lompart, A. Pietruszka, Mirosława Puskullouglu, A. Grela-Wojewoda","doi":"10.5603/njo.a2023.0020","DOIUrl":null,"url":null,"abstract":"A 36-year old female was diagnosed with a breast infiltrating duct carcinoma, NOS, G2, luminal B HER2-neg, metastatic to the lymph nodes, lungs, liver and bones. She received ribociclib, fulvestrant and LHRH analog for 15 months with partial remission. For personal reasons the patient interrupted therapy for 4 months, but reported afterwards due to rapid progression. A core-biopsy revealed no presence of usual infiltrating duct carcinoma, but unequivocal choriocarcinoma-tous differentiation with mononuclear cytotrophoblast-like cells with hyperchromatic nuclei and multinucleated syncy-tiotrophoblast-like giant cells (fig. 1) and strong cytoplasmatic immunoreactivity for β-HCG (fig. 2). Pathologist suggested either a rare variant of invasive breast carcinoma with a cho-riocarcinomatous pattern or metastatic choriocarcinoma to the breast. Metastatic progression was seen; pregnancy, as well as primary choriocarcinoma were excluded; total β-HCG was 80,000 mU/ml. The patient received cisplatin plus etoposide with moderate clinical improvement and rapid decrease of β-HCG level. Invasive carcinoma","PeriodicalId":130080,"journal":{"name":"Nowotwory. Journal of Oncology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nowotwory. Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/njo.a2023.0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A 36-year old female was diagnosed with a breast infiltrating duct carcinoma, NOS, G2, luminal B HER2-neg, metastatic to the lymph nodes, lungs, liver and bones. She received ribociclib, fulvestrant and LHRH analog for 15 months with partial remission. For personal reasons the patient interrupted therapy for 4 months, but reported afterwards due to rapid progression. A core-biopsy revealed no presence of usual infiltrating duct carcinoma, but unequivocal choriocarcinoma-tous differentiation with mononuclear cytotrophoblast-like cells with hyperchromatic nuclei and multinucleated syncy-tiotrophoblast-like giant cells (fig. 1) and strong cytoplasmatic immunoreactivity for β-HCG (fig. 2). Pathologist suggested either a rare variant of invasive breast carcinoma with a cho-riocarcinomatous pattern or metastatic choriocarcinoma to the breast. Metastatic progression was seen; pregnancy, as well as primary choriocarcinoma were excluded; total β-HCG was 80,000 mU/ml. The patient received cisplatin plus etoposide with moderate clinical improvement and rapid decrease of β-HCG level. Invasive carcinoma
乳腺浸润性癌伴绒毛膜癌
女性,36岁,诊断为乳腺浸润导管癌,NOS, G2,管腔B her2阴性,转移至淋巴结,肺,肝和骨骼。她接受了核糖西尼、氟维司汀和LHRH类似物治疗15个月,部分缓解。患者因个人原因中断治疗4个月,但因病情迅速进展后报告。核心活检未发现常见的浸润性导管癌,但明确的绒毛膜癌分化为单核细胞滋养细胞样细胞,细胞核深染,多核同质滋养细胞样巨细胞(图1)和β-HCG的强细胞质免疫反应性(图2)。病理学家认为这是一种罕见的浸润性乳腺癌,伴有绒毛膜癌模式或转移性乳腺绒毛膜癌。有转移进展;排除妊娠、原发性绒毛膜癌;总β-HCG为80000 mU/ml。患者接受顺铂加依托泊苷治疗,临床改善中度,β-HCG水平迅速下降。浸润性癌
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信